Search

ProQR at TIDES to highlight our Axiomer® technology

Blog

This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.

November 17, 2022
ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference

Press release

… ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference LEIDEN, The Netherlands, June 04, 2018 (GLOBE …

Juni 04, 2018
ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences

Press release

Key Updates

September 19, 2017
ProQR to Present at Upcoming Scientific and Industry Conferences

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

März 07, 2023
ProQR Announces First Quarter 2023 Operating and Financial Results

Press release

Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1 Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas Stre

Mai 16, 2023
ProQR Announces Results for the Third Quarter of 2017

Press release

… QR-313 pre-clinical data was presented at the EB2017 Research Conference and ESDR Meeting, both in Salzburg, Austria. A …

November 20, 2017
ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update

Press release

… technology was introduced at the Company’s second annual Research & Development Investor Day and in vivo proof of … F508del mutation were presented at the North American CF conference. A Phase 2 study is currently being designed and … QR-313 pre-clinical data were presented at the EB2017 Research Conference and ESDR meeting. IND-enabling studies …

Februar 28, 2018